Standard BioTools
LAB
125 hedge funds and large institutions have $296M invested in Standard BioTools in 2019 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 41 reducing their positions, and 31 closing their positions.
503% more call options, than puts
Call options by funds: $1.56M | Put options by funds: $258K
12% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 41
7% less funds holding
Funds holding: 135 → 125 (-10)
9.63% less ownership
Funds ownership: 101.67% → 92.04% (-9.6%)
32% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 31
66% less capital invested
Capital invested by funds: $864M → $296M (-$569M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
ICM
Indaba Capital Management
San Francisco,
California
|
+$21.4M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$13.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.17M |
| 4 |
D.E. Shaw & Co
New York
|
+$4.24M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$3.12M |
Top Sellers
| 1 |
EIP
Easterly Investment Partners
Beverly,
Massachusetts
|
-$22.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$22.4M |
| 3 |
Morgan Stanley
New York
|
-$11.7M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$11.3M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$7.54M |
LAB Hedge Fund Activity: Q3 2019 in Review
125 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2019, worth a combined $296M — down 66% from $864M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of LAB and 21 opened new positions — a net loss of 10 holders — while 41 trimmed existing stakes and 46 added.
The largest buyer was Indaba Capital Management, opening a new position worth an estimated $21.4M. The largest seller was Easterly Investment Partners, cutting an estimated $22.7M.
- 125 institutional investors held Standard BioTools (LAB) as of Q3 2019, down from 135 in Q2 2019.
- Funds reported $296M of Standard BioTools stock for Q3 2019, down 66% quarter-over-quarter.
- 21 funds opened new Standard BioTools positions in Q3 2019 and 31 closed out, a net change of -10 holders.
- The largest Standard BioTools buyer in Q3 2019 was Indaba Capital Management, an estimated $21.4M added.
- The largest Standard BioTools seller in Q3 2019 was Easterly Investment Partners, an estimated $22.7M sold.
Based on aggregated 13F filings for Q3 2019.